| Literature DB >> 27205903 |
Adalbjorg Kristbjornsdottir1, Thor Aspelund1, Vilhjalmur Rafnsson2.
Abstract
BACKGROUND: Residents of geothermal areas have higher incidence of non-Hodgkin's lymphoma, breast cancer, prostate cancer, and kidney cancers than others. These populations are exposed to chronic low-level ground gas emissions and various pollutants from geothermal water. The aim was to assess whether habitation in geothermal areas and utilisation of geothermal water is associated with risk of cancer according to duration of residence.Entities:
Mesh:
Year: 2016 PMID: 27205903 PMCID: PMC4874673 DOI: 10.1371/journal.pone.0155922
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics in the geothermal heating area and the two reference areas, categories of cumulative years of residence in the respective areas, number of individual, and age at census.
| Geothermal heating area | Warm reference area | Cold reference area | |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Number of people | 7511 (100) | 44 864 (100) | 22 431 (100) |
| Mean ± SD | 28.81 ± 16.35 | 28.65 ± 16.30 | 28.56 ± 16.20 |
| Median, IQR (0.25; 0.75) | 26 (15; 41) | 26 (15; 40) | 26 (15; 40) |
| < 5 years | 1479 (19.7) | 6935 (15.5) | 4029 (18.0) |
| ≥ 5 to <10 years | 1061 (14.1) | 5808 (12.9) | 3213 (14.3) |
| ≥ 10 to < 15 years | 843 (11.2) | 5688 (12.7) | 2853 (12.7) |
| ≥ 15 to < 20 years | 671 (8.9) | 3829 (8.5) | 1880 (8.4) |
| ≥ 20 to < 24 years | 492 (6.6) | 3235 (7.2) | 1861 (8.3) |
| ≥ 24 years | 2965 (39.5) | 19 369 (43.2) | 8595 (38.3) |
| < 5 years | |||
| Mean ± SD | 26.83 ± 14.78 | 26.71 ± 14.93 | 26.16 ± 14.54 |
| Median, IQR (0.25; 0.75) | 23 (17; 34) | 24 (17; 34) | 24 (16; 33) |
| ≥ 5 to <10 years | |||
| Mean ± SD | 24.67 ± 15.86 | 25.09 ± 15.66 | 25.39 ± 15.77 |
| Median, IQR (0.25; 0.75) | 19 (14; 33) | 20 (14; 34) | 20 (14; 33) |
| ≥ 10 to < 15 years | |||
| Mean ± SD | 25.48 ± 17.09 | 26.92 ± 17.25 | 27.02 ± 17.56 |
| Median, IQR (0.25; 0.75) | 18 (12; 36) | 20 (13; 39) | 20 (13; 40) |
| ≥ 15 to < 20 years | |||
| Mean ± SD | 27.93 ± 20.24 | 27.88 ± 19.86 | 26.96 ± 19.20 |
| Median, IQR (0.25; 0.75) | 19 (9; 48) | 22 (9; 47) | 21 (10; 44) |
| ≥ 20 to < 24 years | |||
| Mean ± SD | 31.75 ± 18.79 | 31.07 ± 19.14 | 30.24 ± 18.28 |
| Median, IQR (0.25; 0.75) | 32 (13; 49) | 30 (12; 49) | 28 (13; 46) |
| ≥ 24 years | |||
| Mean ± SD | 31.95 ± 14.88 | 30.66 ± 14.97 | 31.38 ± 14.86 |
| Median, IQR (0.25; 0.75) | 31 (20; 43) | 30 (19; 42) | 30 (20; 42) |
Abbreviations: SD standard deviation, IQR inter-quartile range.
Fig 1Kaplan-Meier estimates of event free proportion for all cancers since the census 1981, dashed line indicate population in geothermal heating area, and black line population in the cold reference area.
Fig 2Kaplan-Meier estimates of event free proportion for breast cancer, prostate cancer, pancreas cancer and non-Hodgkin’s lymphoma (NHL) since the census 1981.
Dashed line indicates population in geothermal heating area, and black line population in the cold reference area.
Number of all cancers and selected cancer sites among men and women combined, hazard ratio (HR), 95% confidence intervals (CI) compared with the populations in warm reference area and cold reference area, adjusted for age, gender, education, type of housing, and smoking habits, without and with stratification into categories of cumulative years of residence in the respective areas.
| Geothermal heating area | Warm reference area | Cold reference area | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of cancers | No of cancers | Not stratified | Stratified | No of cancers | Not stratified | Stratified | |||||
| Cancers (ICD-10) | HR | 95%CI | HR | 95%CI | HR | 95%CI | HR | 95%CI | |||
| All (C00-C97, D45-D47) | 988 | 5331 | 1.06 | 0.99–1.14 | 2524 | ||||||
| Pancreas (C25) | 30 | 126 | 1.50 | 0.99–2.27 | 49 | ||||||
| Lung and bronchus (C33-C34) | 92 | 578 | 0.91 | 0.72–1.14 | 0.94 | 0.75–1.18 | 300 | 0.92 | 0.73–1.17 | 0.96 | 0.76–1.22 |
| Breast (C50) | 161 | 740 | 326 | ||||||||
| Prostate (C61) | 172 | 803 | 377 | ||||||||
| Kidney (C64-C66) | 49 | 241 | 1.21 | 0.88–1.67 | 1.27 | 0.92–1.75 | 103 | ||||
| Lymphoid and haematopoietic tissue (LH) (C81-C96, D45-D47) | 97 | 419 | 199 | ||||||||
| Non-Hodgkin´s lymphoma (NHL) (C82-C85) | 39 | 137 | 62 | ||||||||
| NHL, peripheral T-cells (C84) | 6 | 14 | 5 | ||||||||
| NHL, unspecified (C85) | 9 | 11 | 4 | ||||||||
| Leukaemia (C91-C95, D45-D47) | 30 | 145 | 1.10 | 0.73–1.65 | 1.13 | 0.75–1.70 | 71 | 1.30 | 0.85–2.00 | 1.37 | 0.89–2.11 |
| Chronic lymphocytic leukaemia (CLL)(C91.1) | 10 | 45 | 1.16 | 0.57–2.35 | 1.22 | 0.59–2.49 | 24 | 1.30 | 0.62–2.73 | 1.45 | 0.68–3.08 |
| Non-CLL (C91-C95, D45-D47, except C91.1) | 20 | 100 | 1.07 | 0.65–1.76 | 1.09 | 0.67–1.80 | 47 | 1.31 | 0.77–2.22 | 1.35 | 0.80–2.29 |
| Myelodysplastic syndromes (MDS) (D46) | 8 | 18 | 2.31 | 0.95–5.58 | 6 | ||||||
| MDS, unspecified (D46.9) | 8 | 12 | 3 | ||||||||
| Other LH, uncertain (D47) | 3 | 14 | 1.24 | 0.34–4.54 | 1.41 | 0.38–5.21 | 7 | 1.21 | 0.31–4.70 | 1.14 | 0.29–4.44 |
| Other LH thrombocythemia (D47.3) | 3 | 2 | 1 | 8.61 | 0.85–86.98 | 7.53 | 0.74–76.48 | ||||
| Not included in all cancers | |||||||||||
| Basal cell carcinoma of skin (C44) | 177 | 781 | 335 | ||||||||
Statistically significant HRs are bolded.
a 95%CI computed with bootstrap method did not include unity.
b 95%CI computed with bootstrap method included unity.
* p < 0.05
** p < 0.01
*** p < 0.005.
Number of all cancers and selected cancer sites among men and women combined, hazard ratio (HR), 95% confidence intervals (CI) compared with the populations in warm reference area and cold reference area applying five years latency time, adjusted for age, gender, education, type of housing, and smoking habits, without and with stratification into categories of cumulative years of residence in the respective areas.
| Geothermal heating area | Warm reference area | Cold reference area | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No of cancers | No of cancers | Not stratified | Stratified | No of cancers | Not stratified | Stratified | |||||
| Cancers (ICD-10) | HR | 95%CI | HR | 95%CI | HR | 95%CI | HR | 95%CI | |||
| All (C00-C97, D45-D47) | 372 | 1845 | 1.11 | 0.99–1.25 | 959 | ||||||
| Pancreas (C25) | 11 | 36 | 1.92 | 0.94–3.91 | 19 | 1.90 | 0.90–4.00 | 2.01 | 0.95–4.25 | ||
| Lung and bronchus (C33-C34) | 40 | 209 | 1.01 | 0.71–4.42 | 1.03 | 0.72–1.46 | 126 | 0.99 | 0.69–1.41 | 1.01 | 0.71–1.45 |
| Breast (C50) | 56 | 277 | 1.11 | 0.82–1.49 | 1.14 | 0.85–1.54 | 133 | 1.28 | 0.94–1.75 | 1.29 | 0.94–1.76 |
| Prostate (C61) | 57 | 288 | 1.15 | 0.85–1.54 | 1.21 | 0.90–1.63 | 138 | 1.31 | 0.96–1.79 | 1.35 | 0.98–1.85 |
| Kidney (C64-C66) | 16 | 90 | 1.03 | 0.59–1.78 | 1.06 | 0.61–1.84 | 41 | 1.17 | 0.66–2.09 | 1.18 | 0.66–2.10 |
| Lymphoid and haematopoietic tissue (LH) (C81-C96, D45-D47) | 37 | 143 | 72 | ||||||||
| Non-Hodgkin´s lymphoma (NHL) (C82-C85) | 17 | 49 | 20 | ||||||||
| NHL, peripheral T-cells (C84) | 4 | 5 | 2 | ||||||||
| NHL, unspecified (C85) | 3 | 0 | 1 | 10.23 | 0.96–108.93 | ||||||
| Leukaemia (C91-C95, D45-D47) | 10 | 50 | 1.08 | 0.53–2.18 | 1.22 | 0.60–2.49 | 28 | 1.11 | 0.54–2.28 | 1.25 | 0.60–2.59 |
| Chronic lymphocytic leukaemia (CLL)(C91.1) | 1 | 15 | 0.35 | 0.05–2.71 | 0.41 | 0.05–3.21 | 8 | 0.40 | 0.06–2.87 | 0.59 | 0.07–4.93 |
| Non-CLL (C91-C95, D45-D47, except C91.1) | 9 | 35 | 1.40 | 0.65–3.01 | 1.58 | 0.73–3.42 | 20 | 1.40 | 0.64–3.09 | 1.48 | 0.67–3.26 |
| Myelodysplastic syndromes (MDS) (D46) | 7 | 10 | 2 | ||||||||
| MDS, unspecified (D46.9) | 7 | 6 | 1 | ||||||||
| Other LH, uncertain (D47) | 1 | 1 | 6.34 | 0.34–118.41 | 8.68 | 0.44–170.13 | 0 | ||||
| Other LH thrombocythemia (D47.3) | 1 | 1 | 6.34 | 0.34–118.41 | 8.68 | 0.44–170.13 | 0 | ||||
| Not included in all cancers | |||||||||||
| Basal cell carcinoma of skin (C44) | 74 | 357 | 1.06 | 0.82–1.37 | 1.11 | 0.86–1.44 | 154 | ||||
Statistically significant HRs are bolded.
a 95%CI computed with bootstrap method did not include unity.
b 95%CI computed with bootstrap method included unity.
* p < 0.05
** p < 0.01
*** p < 0.005.